AbstractObjective To investigate the clinical efficacy of liraglutide and empagliflozin combined with insulin in the treatment of type 2 diabetes. Methods A total of 180 patients with type 2 diabetes who were treated in our hospital were selected and divided into observation group（90 cases）and control group（90 cases）according to the double-blind method.The observation group was treated with liraglutide combined with insulin,and the control group was treated with empagliflozin combined with insulin.Participants received 0.9 mg/d liraglutide or 10 mg/d epagliflozin for 24 weeks.The HbA1c（glycated hemoglobin）,GA（glycated albumin）,and PPG（postprandial plasma glucose）of the two groups after 24 weeks of treatment were compared. Results The HbA1c（glycated hemoglobin）（6.80±0.14）% of the observation group after 24 weeks of treatment was less than the HbA1c（glycated hemoglobin）（7.73±0.83）% of the control group after 24 weeks of treatment.The difference was statistically significant（P<0.05）.GA（glycated albumin）（18.32±0.42）% after 24 weeks of treatment was less than that of the control group after 24 weeks of treatment（19.49±0.29）%,the difference was statistically significant（P<0.05）,the observation group was treated After 24 weeks,PPG（postprandial plasma glucose）（159.01±8.89）% was less than that of the control group after 24 weeks of treatment（172.16±10.64）%,the difference was statistically significant（P<0.05）. Conclusion In patients with inadequate control of type 2 diabetes,in addition to ongoing insulin therapy,liraglutide is more effective than empagliflozin in reducing the levels of glycosylated hemoglobin and glycosylated albumin,which is worthy of clinical promotion.
Zheng Yu. Effects of Liraglutide and Empagliflflozin Added to Insulin Therapy in Patients With Type 2 Diabetes：A Randomized Controlled Study[J]. journal1, 2022, 42(6): 4-6.
[1] 崔克勤,王海燕,唐键,等.利拉鲁肽单药治疗新诊超重或肥胖2型糖尿病的效果及安全性观察[J].山东医药,2016,56(30):47-49. [2] 王建中. Semaglutide降低2型糖尿病患者的心脑血管事件风险[J].中华肾病研究电子杂志,2016,32(5):24-56. [3] 德鲁克等. 肠促胰岛素激素的生物学[J].细胞代,2016,13(3):153-165. [4] 田勍,洪天配.基础胰岛素与胰高血糖素样肽-1受体激动剂联合治疗糖尿病的合理性[J].中国糖尿病杂志,2012,4(8):500-502. [5] 沈和荣. 格列美脲联合治疗单用胰岛素效果不佳2型糖尿病患者的临床观察[J].医药论坛杂志,2013,54(11):19-20. [6] 钱荣立. 解读美国糖尿病学会与欧洲糖尿病研究协会关于“以患者为中心的2型糖尿病高血糖管理方案”的立场声明[J].中国糖尿病杂志,2013,21(1):5-6. [7] 朱振航,陈凤玲.GLP-1RA在糖尿病神经病变治疗中潜在作用及机制研究进展[J].医学综述,2017,56(10):12-457. [8] Seino Y,Kaneko S,Fukuda S,et al:Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes:a 36-week,randomized,double-blind,parallel-group trial[J].Diabetes Investig,2016,15(7):565-573. [9] 陶晓明、蒋翠萍、黄宇新,等.二甲双胍联合磺脲类降糖药或二肽基肽酶4抑制剂在全面血糖控制上的差异[J].中国临床药学杂志,2020,29(6):31-35. [10] 范莉萍,孙丽,朱志良.沙格列汀及二甲双胍联合应用对非肥胖2型糖尿病患者体重及体脂变化的影响[J].中国保健营养,2019,29(23):31-32. [11] Araki E,Onishi Y,Asano M,et al.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes:the DAISY(Dapagliflozin Added to patients under InSulin therapY)trial[J].Diabetes Obes Metab,2017,16(19):562-570. [12] 周洋,石秀锦,彭文星等.2014-2018年我国七城市二肽基肽酶Ⅳ抑制剂和胰高血糖素样肽1受体激动剂及钠-葡萄糖共转运蛋白2抑制剂使用情况调查[J].中国医药,2020,15(1):130-134. [13] Mann JFE,rsted DD,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes.N Engl[J].Med,2017,11(377):839-848. [14] 赵凡,丁国华.2型糖尿病肾病患者肾血流阻力指数与血清脂蛋白a对肾功能进展的预测[J].医学研究杂志,2019,13(11):24-30.
2022, Vol. 42 
